[HTML][HTML] Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients
S Sridhar, L Paz-Ares, H Liu, K Shen, C Morehouse… - Clinical Lung Cancer, 2019 - Elsevier
Abstract Introduction Two clinical studies (Study 1108 and ATLANTIC) were analyzed to
evaluate the prognostic value of baseline liver metastases (LMs) in advanced/metastatic non …
evaluate the prognostic value of baseline liver metastases (LMs) in advanced/metastatic non …
Who benefits the most from adjuvant durvalumab after chemoradiotherapy for non-small cell lung cancer? An exploratory analysis
Purpose Adjuvant durvalumab is now recommended for most patients with locally advanced
non-small cell lung cancer after concurrent chemoradiotherapy. Herein, we explore the …
non-small cell lung cancer after concurrent chemoradiotherapy. Herein, we explore the …
[HTML][HTML] 1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small …
Background Major pathological response after neoadjuvant cisplatin-based chemotherapy
for early-stage NSCLC has been shown to predict survival. This has not been demonstrated …
for early-stage NSCLC has been shown to predict survival. This has not been demonstrated …
Dynamics of early serum tumour markers and neutrophil-to-lymphocyte ratio predict response to PD-1/PD-L1 inhibitors in advanced non-small-cell lung cancer
Y Tang, Y Cui, L Li, Y Guan, D Feng, B Yin… - Cancer Management …, 2021 - Taylor & Francis
Purpose To evaluate the dynamics of early serum tumour markers (STMs) and the neutrophil-
to-lymphocyte ratio (NLR) to predict clinical efficacy and prognosis of advanced non-small …
to-lymphocyte ratio (NLR) to predict clinical efficacy and prognosis of advanced non-small …
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Introduction The safety of first-line (1L) durvalumab in patients with advanced nonsmall-cell
lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance …
lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance …
Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study …
T Sakaguchi, K Ito, K Furuhashi, Y Nakamura… - Respiratory …, 2019 - Elsevier
Background Compared to a placebo, durvalumab has been reported to significantly prolong
progression-free and overall survival in patients with stage III unresectable non-small cell …
progression-free and overall survival in patients with stage III unresectable non-small cell …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
Background: Durvalumab (D), a human IgG1 mAb against PD-1 and CD80, has shown
clinical activity in patients (pts) with non-small cell lung cancer (NSCLC). Tremelimumab (T) …
clinical activity in patients (pts) with non-small cell lung cancer (NSCLC). Tremelimumab (T) …
[HTML][HTML] Real-world analysis of durvalumab after chemoradiation in stage III non-small-cell lung cancer
BTB Preti, MS Sanatani, D Breadner, S Lakkunarajah… - Current …, 2023 - mdpi.com
The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following
curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However …
curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However …
Corrigendum: a real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage iii non …
1 Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of
Modena, Modena, Italy, 2 Department of Oncology, Radiation Therapy Unit, Careggi …
Modena, Modena, Italy, 2 Department of Oncology, Radiation Therapy Unit, Careggi …